<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
<channel>
<title>Entera Bio Ltd — News on 6ix</title>
<link>https://6ix.com/company/entera-bio-ltd</link>
<description>Latest news and press releases for Entera Bio Ltd on 6ix.</description>
<language>en-us</language>
<lastBuildDate>Tue, 14 Apr 2026 12:45:00 GMT</lastBuildDate>
<generator>6ix RSS</generator>
<atom:link href="https://6ix.com/rss/company/entera-bio-ltd" rel="self" type="application/rss+xml" />
<image>
<url>https://6ix-events-pro.s3.amazonaws.com/6ixvideo/logos/org-logo6835638978dffbe2df0ef4a7.webp</url>
<title>Entera Bio Ltd</title>
<link>https://6ix.com/company/entera-bio-ltd</link>
</image>
<item>
<title>Entera Bio to Host Key Opinion Leader Webinar Highlighting the Osteoporosis Treatment Landscape and the Opportunity for EB613</title>
<link>https://6ix.com/company/entera-bio-ltd/news/entera-bio-to-host-key-opinion-leader-webinar-highlighting-the-osteoporosis-treatment-landscape-and-the-opportunity-for-eb613</link>
<guid isPermaLink="true">https://6ix.com/company/entera-bio-ltd/news/entera-bio-to-host-key-opinion-leader-webinar-highlighting-the-osteoporosis-treatment-landscape-and-the-opportunity-for-eb613</guid>
<pubDate>Tue, 14 Apr 2026 12:45:00 GMT</pubDate>
<description>TEL AVIV, Israel, April 14, 2026 (GLOBE NEWSWIRE) -- TEL AVIV, Israel, April 14, 2026 -- Entera Bio Ltd. (Nasdaq: ENTX) (“Entera” or the “Company”), a leader in the development of oral peptides, today announced it will host a virtual Key Opinion Leader (KOL) webinar focused on the osteoporosis treatment landscape and the opportunity for its lead clinical candidate, EB613 (oral PTH (1-34) tablet), on Monday, April 20, 2026 at 11:00 AM Eastern Time. Attendance for the event requires registration.</description>
</item>
<item>
<title>Entera Bio Announces Pricing of $10.0 Million Direct Investment by BVF Partners with Potential for up to $24.5 Million in Total Proceeds</title>
<link>https://6ix.com/company/entera-bio-ltd/news/entera-bio-announces-pricing-of-dollar100-million-direct-investment-by-bvf-partners-with-potential-for-up-to-dollar245-million-in-total-proceeds-47</link>
<guid isPermaLink="true">https://6ix.com/company/entera-bio-ltd/news/entera-bio-announces-pricing-of-dollar100-million-direct-investment-by-bvf-partners-with-potential-for-up-to-dollar245-million-in-total-proceeds-47</guid>
<pubDate>Thu, 02 Apr 2026 04:00:00 GMT</pubDate>
<description>TEL AVIV, Israel, April 02, 2026 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (Nasdaq: ENTX) (“Entera” or the “Company”), a leader in the development of oral peptides,</description>
</item>
<item>
<title>Entera Bio Announces Full Year 2025 Financial Results and Provides Business Updates</title>
<link>https://6ix.com/company/entera-bio-ltd/news/entera-bio-announces-full-year-2025-financial-results-and-provides-business-updates</link>
<guid isPermaLink="true">https://6ix.com/company/entera-bio-ltd/news/entera-bio-announces-full-year-2025-financial-results-and-provides-business-updates</guid>
<pubDate>Fri, 27 Mar 2026 04:00:00 GMT</pubDate>
<description>EB613, the first oral anabolic (bone building) peptide tablet for postmenopausal women with osteoporosis – FDA Type A endpoint alignment in July 2025, Phase 3</description>
</item>
<item>
<title>Entera Bio Submits Streamlined Phase 3 Protocol to Initiate Registrational Program for EB613 in Postmenopausal Women with Osteoporosis</title>
<link>https://6ix.com/company/entera-bio-ltd/news/entera-bio-submits-streamlined-phase-3-protocol-to-initiate-registrational-program-for-eb613-in-postmenopausal-women-with-osteoporosis</link>
<guid isPermaLink="true">https://6ix.com/company/entera-bio-ltd/news/entera-bio-submits-streamlined-phase-3-protocol-to-initiate-registrational-program-for-eb613-in-postmenopausal-women-with-osteoporosis</guid>
<pubDate>Wed, 04 Mar 2026 13:30:00 GMT</pubDate>
<description>Phase 3 study designed with total hip BMD primary endpoint assessed at 12 months, rather than at 24 months EB613 single tablet final commercial formulation (Next-Gen EB613) replaces multi-tablet EB613 as Phase 3 candidate, following successful bridging study Topline data anticipated in the second half of 2028, approximately one year earlier than previously expected; Entera commits to a 12-month extension study to run in parallel with potential NDA review TEL AVIV, March 04, 2026 (GLOBE NEWSWIRE)</description>
</item>
<item>
<title>Matricelf Ltd. (TASE: MTLF) Appoints Ron Mayron as Chairman of the Board</title>
<link>https://6ix.com/company/entera-bio-ltd/news/matricelf-ltd-tase-mtlf-appoints-ron-mayron-as-chairman-of-the-board-2</link>
<guid isPermaLink="true">https://6ix.com/company/entera-bio-ltd/news/matricelf-ltd-tase-mtlf-appoints-ron-mayron-as-chairman-of-the-board-2</guid>
<pubDate>Fri, 27 Feb 2026 12:00:00 GMT</pubDate>
<description>Matricelf Ltd. (TASE: MTLF), a biotechnology company developing autologous engineered tissue therapies, today announced the appointment of Mr. Ron Mayron as Active Chairman of the Board of Directors. Mr. Mayron's appointment follows shareholder approval and submission of his formal Director Eligibility Declaration in accordance with the Israeli Companies Law.</description>
</item>
<item>
<title>Entera Bio to Participate in the Leerink Partners 2026 Global Healthcare Conference</title>
<link>https://6ix.com/company/entera-bio-ltd/news/entera-bio-to-participate-in-the-leerink-partners-2026-global-healthcare-conference</link>
<guid isPermaLink="true">https://6ix.com/company/entera-bio-ltd/news/entera-bio-to-participate-in-the-leerink-partners-2026-global-healthcare-conference</guid>
<pubDate>Thu, 26 Feb 2026 05:00:00 GMT</pubDate>
<description>TEL AVIV, Feb. 26, 2026 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ: ENTX) ("Entera" or the "Company"), a leader in the development of oral peptide and</description>
</item>
<item>
<title>Entera Bio Announces Open Market Purchases of Company Stock by Board Members</title>
<link>https://6ix.com/company/entera-bio-ltd/news/entera-bio-announces-open-market-140000711</link>
<guid isPermaLink="true">https://6ix.com/company/entera-bio-ltd/news/entera-bio-announces-open-market-140000711</guid>
<pubDate>Wed, 11 Feb 2026 14:00:00 GMT</pubDate>
<description>TEL AVIV, Feb. 11, 2026 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ: ENTX) ("Entera" or the "Company"), a leader in the development of oral peptide and protein replacement therapies, today announced that several members of its Board of Directors, including the Company’s Chairman, have made open market purchases of the Company’s ordinary shares. These transactions follow an earlier open market purchase by Entera Bio’s Chief Executive Officer, Miranda Toledano, in December 2025. The purchases were</description>
</item>
<item>
<title>Entera Bio Appoints Former Pfizer Executive Geno J. Germano as Chairman of the Board Ahead of Key Milestones</title>
<link>https://6ix.com/company/entera-bio-ltd/news/entera-bio-appoints-former-pfizer-135000762</link>
<guid isPermaLink="true">https://6ix.com/company/entera-bio-ltd/news/entera-bio-appoints-former-pfizer-135000762</guid>
<pubDate>Mon, 09 Feb 2026 13:50:00 GMT</pubDate>
<description>New Chairman Joins Entera’s Board with Senior Global Leadership Experience from Pfizer, Wyeth and Other Leading Biopharma Companies as Entera Advances Multiple Oral Peptide Programs Toward Significant Milestones in 2026TEL AVIV, Feb. 09, 2026 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ: ENTX) ("Entera" or the "Company"), a leader in the development of oral peptide and protein replacement therapies, today announced that its Board of Directors has appointed Geno J. Germano as Chairman of the Board</description>
</item>
<item>
<title>OPKO Health and Entera Bio Expand Partnership to Advance First-in-Class Oral Long Acting PTH Tablet for Patients with Hypoparathyroidism</title>
<link>https://6ix.com/company/entera-bio-ltd/news/opko-health-entera-bio-expand-130000575</link>
<guid isPermaLink="true">https://6ix.com/company/entera-bio-ltd/news/opko-health-entera-bio-expand-130000575</guid>
<pubDate>Wed, 04 Feb 2026 13:00:00 GMT</pubDate>
<description>This is the third program that successfully combines Entera’s oral peptide N-Tab® platform with OPKO’s advanced protein chemistry capabilities The companies have accelerated this program and aim to file an investigational new drug (IND) application in late 2026 Injectable and oral oxyntomodulin (dual GLP-1/glucagon analog) for metabolic and fibrotic disorders advancing with initial Phase 1 data from injectable oxyntomodulin (OXM) expected in late 2026; oral OXM to enter clinic thereafter Industr</description>
</item>
<item>
<title>Entera Bio Announces Upcoming Q1 2026 Corporate Priorities and Pipeline Outlook</title>
<link>https://6ix.com/company/entera-bio-ltd/news/entera-bio-announces-upcoming-q1-133000843</link>
<guid isPermaLink="true">https://6ix.com/company/entera-bio-ltd/news/entera-bio-announces-upcoming-q1-133000843</guid>
<pubDate>Wed, 21 Jan 2026 13:30:00 GMT</pubDate>
<description>Final EB613 Phase 3 Protocol Submission to FDA Planned for Q1 2026, Following December 19th 2025 FDA Ruling Next-Generation EB613 Phase 1 Bridging Study Progressing with Results Expected During Q1 2026 Oral Hypoparathyroidism Tablet Program to Accelerate with Lead Long-Acting PTH Variants Strategic Partnership Discussions Advancing Across Pipeline JERUSALEM, Jan. 21, 2026 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ: ENTX) ("Entera" or the "Company"), a leader in the development of oral peptide a</description>
</item>
<item>
<title>Entera Bio Congratulates the FNIH-ASBMR-SABRE Team on FDA’s Qualification of Total Hip BMD as Regulatory Endpoint: Huge Win for Osteoporosis Innovation</title>
<link>https://6ix.com/company/entera-bio-ltd/news/entera-bio-congratulates-fnih-asbmr-133000773</link>
<guid isPermaLink="true">https://6ix.com/company/entera-bio-ltd/news/entera-bio-congratulates-fnih-asbmr-133000773</guid>
<pubDate>Tue, 23 Dec 2025 13:30:00 GMT</pubDate>
<description>FDA qualification of Total Hip BMD as a validated surrogate endpoint for novel osteoporosis drug development further bolsters Entera's July 2025 FDA alignment and regulatory strategy for EB613 Underscores Entera's mission to democratize anabolic treatment for osteoporosis patients and caregivers globally JERUSALEM, Dec. 23, 2025 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ: ENTX) ("Entera" or the "Company"), a leader in the development of oral peptide and protein replacement therapies, is thrille</description>
</item>
<item>
<title>Entera Bio Announces New Data Supporting Further Development of a Proprietary First-in-Class Oral, Long-Acting PTH Tablet for Patients with Hypoparathyroidism (EB612 Program)</title>
<link>https://6ix.com/company/entera-bio-ltd/news/entera-bio-announces-data-supporting-133000546</link>
<guid isPermaLink="true">https://6ix.com/company/entera-bio-ltd/news/entera-bio-announces-data-supporting-133000546</guid>
<pubDate>Mon, 22 Dec 2025 13:30:00 GMT</pubDate>
<description>Novel PTH analog achieves sustained calcium elevation for >3 days from single oral tablet, supporting development path toward once-daily alternative to daily injectionsJERUSALEM, Dec. 22, 2025 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ: ENTX) (“Entera” or the “Company”), a leader in the development of oral peptides and proteins replacement therapies, today announced new validating in vivo pharmacokinetic and pharmacodynamic data that supports further development of a proprietary long-acting par</description>
</item>
<item>
<title>Entera Bio to Participate in the 8th Annual Evercore ISI Healthcare Conference</title>
<link>https://6ix.com/company/entera-bio-ltd/news/entera-bio-participate-8th-annual-130000795</link>
<guid isPermaLink="true">https://6ix.com/company/entera-bio-ltd/news/entera-bio-participate-8th-annual-130000795</guid>
<pubDate>Tue, 18 Nov 2025 13:00:00 GMT</pubDate>
<description>JERUSALEM, Nov. 18, 2025 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (Nasdaq: ENTX), (“Entera” or the “Company”) a leader in the development of oral peptide and protein replacement therapies, today announced that the Company’s Chief Executive Officer, Miranda Toledano, will be participating in a fireside chat at the 8th Annual Evercore ISI Healthcare Conference, details as below. 7th Annual Evercore ISI HealthCONx Conference (Fireside Chat and 1x1 Meetings) Date and Time: December 3 at 9:10-9:30AM in Se</description>
</item>
<item>
<title>Entera Bio Announces Third Quarter 2025 Financial Results and Business Updates</title>
<link>https://6ix.com/company/entera-bio-ltd/news/entera-bio-announces-third-quarter-210500454</link>
<guid isPermaLink="true">https://6ix.com/company/entera-bio-ltd/news/entera-bio-announces-third-quarter-210500454</guid>
<pubDate>Fri, 14 Nov 2025 21:05:00 GMT</pubDate>
<description>FDA Agreement on BMD as Primary Endpoint for EB613 Registrational, Phase 3 Study EB613 Phase 2 Data Demonstrating Consistent Efficacy across Younger Post-Menopausal Women with Osteoporosis and its Impact on Trabecular and Cortical Bone Indices, Highlighted at NAMS and ASBMR Next-Generation EB613 Remains on Track for Phase 1 Initiation in Late 2025 Pre-Clinical Data for Oral OXM in Obesity and Oral GLP-2 in Short Bowel Syndrome in Collaboration with OPKO Presented at ENDO2025 and ESPEN JERUSALEM,</description>
</item>
<item>
<title>Entera Bio Presents Positive New Clinical Data from EB613 Phase 2 Trial Demonstrating Significant Bone Density Improvements in Early Postmenopausal Women</title>
<link>https://6ix.com/company/entera-bio-ltd/news/entera-bio-presents-positive-clinical-125000821</link>
<guid isPermaLink="true">https://6ix.com/company/entera-bio-ltd/news/entera-bio-presents-positive-clinical-125000821</guid>
<pubDate>Thu, 23 Oct 2025 12:50:00 GMT</pubDate>
<description>Consistency of BMD gains presented at NAMS 2025 demonstrate EB613’s efficacy in both young postmenopausal women and in women 10 years post-menopause Data further support EB613 potential as a first-in-class oral anabolic treatment option that could dramatically expand patient access to bone-building therapy Entera Plans to Initiate Global Registrational Phase 3 Study Following July 2025 FDA Concurrence JERUSALEM, Oct. 23, 2025 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (Nasdaq: ENTX), a leader in the de</description>
</item>
<item>
<title>Entera Bio to Present New Clinical Data from Phase 2 Trial of EB613 at the 2025 North American Menopause Society (NAMS) Annual Meeting</title>
<link>https://6ix.com/company/entera-bio-ltd/news/entera-bio-present-clinical-data-124500930</link>
<guid isPermaLink="true">https://6ix.com/company/entera-bio-ltd/news/entera-bio-present-clinical-data-124500930</guid>
<pubDate>Thu, 16 Oct 2025 12:45:00 GMT</pubDate>
<description>First-time presentation examining bone outcomes in early postmenopausal womenJERUSALEM, Oct. 16, 2025 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ: ENTX), a leader in the development of oral peptide and protein replacement therapies, today announced that it will present new clinical data from its Phase 2 trial of EB613 at the upcoming North American Menopause Society (NAMS) 2025 Annual Meeting, taking place October 21–25, 2025, in Orlando, Florida. This will mark Entera’s first presentation at NA</description>
</item>
<item>
<title>Entera Bio Reports Positive PK Data for First-in-Class Oral GLP-2 Tablet Treatment for Patients with Short Bowel Syndrome at the 2025 ESPEN Congress</title>
<link>https://6ix.com/company/entera-bio-ltd/news/entera-bio-reports-positive-pk-130000236</link>
<guid isPermaLink="true">https://6ix.com/company/entera-bio-ltd/news/entera-bio-reports-positive-pk-130000236</guid>
<pubDate>Mon, 15 Sep 2025 13:00:00 GMT</pubDate>
<description>Preclinical Data for OPK-8801003 Demonstrate Substantially Longer Biological Half-Life with Peak Plasma Levels Comparable to Gattex®, the Only Approved GLP-2 Therapy Oral GLP-2 Tablet Could Transform Treatment Paradigm for 30,000 Short Bowel Syndrome (SBS) Patients Currently Dependent on Daily Injections of the Peptide JERUSALEM, Sept. 15, 2025 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ: ENTX), a leader in the development of oral peptides and protein replacement therapies, today announced the p</description>
</item>
<item>
<title>Entera Bio Presents Positive Effects of EB613 on Both Trabecular and Cortical Bone in Postmenopausal Women with Osteoporosis at ASBMR 2025</title>
<link>https://6ix.com/company/entera-bio-ltd/news/entera-bio-presents-positive-effects-123000337</link>
<guid isPermaLink="true">https://6ix.com/company/entera-bio-ltd/news/entera-bio-presents-positive-effects-123000337</guid>
<pubDate>Mon, 08 Sep 2025 12:30:00 GMT</pubDate>
<description>EB613 Demonstrates Significant Effects on Both Trabecular and Cortical Bone Compartments After Just 6 Months of Treatment in Phase 2 Study; Cortical Improvements Comparable to Injectable Teriparatide and Abaloparatide Company Plans to Initiate Global Registrational Phase 3 Study Following July 2025 FDA Concurrence Entera also Presented Promising Pharmacokinetic Data for Next-Gen EB613 Single Tablet Candidate as Potential Future Franchise Extension JERUSALEM, Sept. 08, 2025 (GLOBE NEWSWIRE) -- En</description>
</item>
<item>
<title>Entera Bio to Unveil Clinical and Non-Clinical Data Across 3 Oral Peptide Programs at Upcoming September Conferences</title>
<link>https://6ix.com/company/entera-bio-ltd/news/entera-bio-unveil-clinical-non-120000677</link>
<guid isPermaLink="true">https://6ix.com/company/entera-bio-ltd/news/entera-bio-unveil-clinical-non-120000677</guid>
<pubDate>Thu, 28 Aug 2025 12:00:00 GMT</pubDate>
<description>Osteoporosis Program: Phase 2 analysis exploring the dual actions of oral PTH(1-34) tablet treatment, EB613 on trabecular and cortical bone, and Next-Gen EB613 PK/PD data slated for oral and poster presentations at ASBMRShort Bowel Syndome and Rare GI Disorders: PK/PD of oral GLP-2 tablet candidate poster presentation at ESPENCorporate Overview at H.C. Wainwright Investor Conference JERUSALEM, Aug. 28, 2025 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ: ENTX), a leader in the development of oral p</description>
</item>
<item>
<title>Entera Bio Announces Second Quarter 2025 Financial Results and Business Updates</title>
<link>https://6ix.com/company/entera-bio-ltd/news/entera-bio-announces-second-quarter-200500050</link>
<guid isPermaLink="true">https://6ix.com/company/entera-bio-ltd/news/entera-bio-announces-second-quarter-200500050</guid>
<pubDate>Fri, 08 Aug 2025 20:05:00 GMT</pubDate>
<description>FDA provides pivotal agreement on EB613 Phase 3 design, confirming Bone Mineral Density (BMD) as primary endpoint and clearing streamlined pathway for first oral anabolic osteoporosis treatmentSignificant regulatory and pipeline advancements achieved including FDA waiver of additional safety studies and next-gen EB613 expected to enter Phase 1 in November 2025Strong momentum across OPKO collaboration with obesity program showing promising preclinical data; and EB612 oral PTH directed hypoparathy</description>
</item>
</channel>
</rss>